Shanghai Hanhong Technology
Pharmaceutical building blocks, intermediates, and API manufacturing services.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY100m | Series A | |
| Total Funding | 000k | ||
Shanghai Hanhong Technology Co., Ltd., established in 2003 and headquartered in Shanghai, is a high-tech enterprise specializing in the biomedical field. The company focuses on the research, development, and production of drug molecular building blocks, pharmaceutical intermediates, and active pharmaceutical ingredients (APIs). It also provides integrated Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services, guiding products from molecular blocks to APIs.
The company's core business revolves around three main areas: advanced chemical reagents (primarily building blocks), APIs and intermediates, and custom synthesis. Hanhong Technology has developed significant technical expertise in biocatalysis, chiral chemistry, and green synthesis. Its product portfolio includes a strong focus on unnatural amino acids, protected amino acids, and their derivatives, where it holds a significant market share. The firm operates a 2,200-square-meter R&D center in Fengxian, Shanghai, and has established production bases in Binhai (Jiangsu), Gaotang (Shandong), and Lanzhou (Gansu). These facilities are equipped with over 300 reactors with capacities ranging from 10L to 5000L, enabling custom synthesis from gram to ton scale.
Financially, the company is privately held and venture capital-backed, having completed a Series A funding round of $14 million in December 2023 with investors including Jinshan Capital Group and Shengshan Asset Management. As of 2022, Hanhong Technology reported sales revenue of 210 million yuan and employed 150 people. The leadership team includes CEO Ma Shizhong, a biochemical engineer from East China University of Science and Technology, and CFO Zhou Jianping, a certified public accountant with experience in IPO processes.
Keywords: drug molecular building blocks, active pharmaceutical ingredients, API manufacturing, CRO services, CDMO services, pharmaceutical intermediates, custom synthesis, unnatural amino acids, chiral chemistry, biocatalysis, green synthesis, drug discovery, peptide synthesis, life sciences, biotechnology, chemical reagents, protected amino acids, drug development, pharmaceutical production, China.